- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03781323
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer: A Phase II Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
Rochester, New York, United States, 14642
- University of Rochester, James P. Wilmot Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be >18 years old at time of diagnosis
- Histologically confirmed adenocarcinoma of the rectum from biopsy, defined as adenocarcinoma <15 cm from the anal verge
- Clinical staging including T3N0 tumors, or T1-3 with N1-2a disease
- Patients with lower rectal cancer deemed by surgery to not be candidates for sphincter sparing surgery are eligible to participate
- There must be no evidence of metastatic disease any time prior to initiation of study
- Rectal tumors must be determined as likely requiring total mesorectal excision (TME)
- Participant must be treatment naïve for rectal cancer, with no prior radiation chemotherapy, radiation, or surgery for specific rectal cancer
- No history of prior pelvic radiation
- No prior administration of platinum agents
- No active infections requiring intravenous antibiotics
- No additional active malignancy
- No prior treatment of any malignancy within the past 3 years
Baseline lab work must meet the following parameters:
- Absolute neutrophil count (ANC)>1500/mm3
- Platelet count>100,000/mm3
- Hemoglobin>8.0 g/dL
- Total bilirubin and creatinine < 1.5x upper limit of normal (ULN)
- AST and ALT < 3x ULN
- Women of childbearing potential (WCBP) will be defined as those biologically capable of becoming pregnant. WCBP must be negative for pregnancy testing (urine or blood) and agree to use effective contraception. Viable contraception should be used after trial screening, before initiation of chemotherapy, and throughout the duration of active treatment in the study.
- Participants must be read and explained the purposes of the study, and sign a statement of informed consent prior to participation. Those who do not read or understand English are eligible and may be consented according to institutional federal regulations.
Exclusion Criteria:
- Recurrent or refractory rectal adenocarcinoma
- T1N0, T2N0, T4a, T4b, or N2b tumors
- Any evidence of metastatic disease
- Primary unresectable rectal cancer. A tumor will be considered unresectable when invading adjacent organs such that an en bloc resection cannot achieve negative margins
- Patients with threatened margins, defined as tumor <1 mm from circumferential resection margins or mesorectal fascia
- Patients unable to undergo MRI imaging
- Patient with a history of any arterial thrombotic event within the past 6 months. This includes angina, myocardial infarction, transient ischemic attack, or cerebral vascular accident.
- Patients with history of venous thrombotic episodes such as deep vein thrombosis, pulmonary embolus occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Patients who are anticoagulated for atrial fibrillation or other conditions may participate only if on stable doses of anticoagulant therapy.
- Patients with cardiovascular, hepatic, or renal systemic diseases that would preclude use of chemotherapy
- Peripheral neuropathy>grade 1 by Common Terminology Criteria for Adverse Events, or CTCAEa
- The patient must not be on any clinical trials involving other experimental therapies before or during study treatment
- Women who are currently pregnant or breast-feeding
- Men and women expecting to father/conceive children
- Patients with any other concord medical or psychiatric condition which were deemed inappropriate for entry into the study per the investigator.
- History of other invasive malignancy within the past 3 years, except for adequately treated non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ or carcinoma in situ of the cervix.
aCTCAE version 5.0 from Department of Health and Human Services
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)
Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle. Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours. |
Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle. Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With a Complete Clinical Response.
Time Frame: 1 year
|
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With Survival
Time Frame: 5 years
|
Will be measured by physical exams
|
5 years
|
Proportion of Patients With Survival
Time Frame: 5 years
|
Will be measured by laboratory testing
|
5 years
|
Proportion of Patients With Survival
Time Frame: 5 years
|
Will be measured by proctoscopy
|
5 years
|
Proportion of Patients With Survival
Time Frame: 5 years
|
Will be measured by sigmoidoscopy
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard Dunne, University of Rochester
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UGIC18095
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Rectal Cancer
-
St Vincent's University Hospital, IrelandRecruitingLocally Advanced Rectal Cancer | Pelvic Exenteration | Advanced Pelvic MalignancyIreland
-
Fondazione Policlinico Universitario Agostino Gemelli...Viewray Inc.UnknownLocally Advanced Rectal Cancer | Pathological Complete Response | Neoadjuvant ChemoradiotherapyItaly
-
li xiongSuspendedAdvanced Rectal CancerChina
-
Asan Medical CenterCompletedAdvanced Rectal CancerKorea, Republic of
-
Zhen-Hai LuNot yet recruitingAdvanced Rectal CancerChina
-
Sun Yat-sen UniversityActive, not recruitingAdvanced Rectal CancerChina
-
Jinhua Central HospitalNot yet recruitingLocally Advanced Rectal CancerChina
-
Beijing Friendship HospitalRecruitingLocally Advanced Rectal CancerChina
-
University of MiamiRecruitingLocally Advanced Rectal CancerUnited States
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.RecruitingLocally Advanced Rectal CancerChina
Clinical Trials on FOLFOX
-
Fox Chase Cancer CenterSuspended
-
Jules Bordet InstituteCompleted
-
Canadian Cancer Trials GroupActive, not recruitingRectal CancerUnited States, Canada
-
University of SaskatchewanTerminatedMetastatic Gastro-esophageal AdenocarcinomaCanada
-
Sun Yat-sen UniversityRecruitingHepatocellular CarcinomaChina
-
Istituto Scientifico Romagnolo per lo Studio e...CompletedMetastatic Colorectal CancerItaly
-
Assistance Publique - Hôpitaux de ParisGERCOR - Multidisciplinary Oncology Cooperative GroupCompletedEsophageal Cancer Stage IIIFrance
-
Beijing Tsinghua Chang Gung HospitalRecruitingCholangiocarcinoma, IntrahepaticChina
-
Sun Yat-sen UniversityUnknown
-
King Abdullah Medical CityKing Faisal Specialist Hospital & Research Center; King Saud Medical City; Al...Recruiting